Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
THANK YOU FOR SUBSCRIBING
By
MedTech Outlook | Friday, August 28, 2020
The innovative nature of EnWave’s proprietary drying technology will be a breakthrough in the commercial feasibility of the COVID-19 treatment that its UBC collaborators have been developing.
FREMONT, CA: EnWave Corporation announces collaboration with the University of British Columbia (UBC) to investigate a manufacturing method for a new inhaler with the objective of using it to help provide relief for COVID-19 patients. The Project will be primarily funded by a $50,000 NSERC Alliance government research grant.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
UBC researchers are looking for a drying method that will allow for the encapsulation of microparticles into an inhalable treatment. EnWave’s patented Radiant Energy Vacuum (REV) dehydration technology is a promising option for this specific manufacturing process. UBC researchers involved are Assistant Professor Anubhav Pratap Singh and Professor David Kitts from UBC’s Faculty of Land and Food Systems, and Assistant Professor Mattia Bacca and Postdoctoral Fellow Alberto Baldelli from the Faculty of Applied Sciences. This latest inhalable treatment aims to offer relief to COVID patients while a vaccine is in development. EnWave hopes it can be more accessible, reasonably affordable, and commercialized much sooner.
Presently, there are no preliminary results. However, the research team expects to generate the first prototypes of encapsulated ACE2 by the end of the summer. At the same time, project collaborators from the University of Sydney and St. Paul’s Hospital in Vancouver are going to create data on the toxicology of ACE2 to lung tissue.
Uniformity and process repeatability has demonstrated through the use of REV technology in the pharmaceutical industry. A cGMP REV machine design has been built and has demonstrated fast-drying cycles for vaccines with equal or superior retention of biological activity compared to conventional lyophilization techniques. Competing lyophilization techniques generally take 24 hours or longer to stabilize pharmaceutical products.
Researchers at UBC and EnWave are assessing the feasibility of REV technology for the manufacture of the inhalable ACE2 encapsulated microparticle. The Project will be segmented into two phases, a lab-scale feasibility assessment and a proof of concept trial. Funding for this research has been approved by the Government of Canada through the Natural Sciences and Engineering Research Council (NSERC).
More in News
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
